Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3

Acurx Pharmaceuticals, Inc.

Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).
Cash at Dec 31, 2024: $3.7M, down from $7.5M; raised $6.6M via ATM in 2024 plus $3.6M in direct offerings in early 2025.
Positive EMA guidance for ibezapolstat Phase 3 program aligned with FDA; regulatory pathway for MAA after Phase 3 completion.
Japan patent granted for DNA pol IIIC inhibitors (expires 2039); advancing ACX-375C for MRSA/VRE/Anthrax.
Phase 2 data: 96% clinical cure, 100% sustained cure at 1 month; non-clinical studies show microbiome-restorative potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.